Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

20202,495 citationsJournal Articlebronze Open Access

Authors

George L. Bakris · Bayer (United States)

Rajiv Agarwal · Richard L. Roudebush VA Medical Center

Stefan D. Anker · Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Bertram Pitt · University of Michigan

Luís M. Ruilope · Steno Diabetes Centers

Peter Rossing · University of Copenhagen

Peter Kolkhof

Abstract

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).

Topics & Keywords

Hormonal Regulation and Hypertension Diet and metabolism studies Apelin-related biomedical research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 23, pp. 2219-2229

DOI: 10.1056/nejmoa2025845

Field-Weighted Citation Impact: 166.96